Legacy Advisors’s HilleVax HLVX Stock Holding History

Legacy Advisors’s Portfolio HLVX Stock Details HLVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-103	Closed	-$348K	–	188
2025 Q1	$348K	Buy	+103	New	+$190	0.04%	302

Other funds holding HLVX

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

LMC

Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Legacy Advisors's HLVX Position: Q2 2025 in Review

Legacy Advisors sold out of HilleVax (HLVX) in Q2 2025, closing a stake of 103 shares — an estimated $348K sold.

Legacy Advisors first reported a position in HLVX in Q1 2025 and held it in 1 quarter. The position peaked at $348K in Q1 2025. 74 funds tracked by Wall St. Rank hold HLVX as of Q2 2025.

Legacy Advisors reported no remaining HilleVax position as of Q2 2025 after selling out during the quarter.
Legacy Advisors sold 103 HilleVax shares in Q2 2025, an estimated $348K.
Legacy Advisors first reported a position in HilleVax in Q1 2025 and held it in 1 quarter.
Legacy Advisors's HilleVax position peaked at $348K in Q1 2025.
74 funds tracked by Wall St. Rank held HilleVax as of Q2 2025.

Based on Legacy Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.